Suzuki M, Minowa K, Tajiri H

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 756-758
Archivo PDF: 156.78 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Indolfi G, Thorne C, El Sayed MH, Giaquinto C, Gonzalez-Peralta RP. The challenge of treating children with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2017; 64: 851-4.

2. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment- naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-47.

3. Tajiri H, Tanaka Y, Takano T, Suzuki M, Abukawa D, Miyoshi Y, Shimizu T, et al. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatol Res 2014; 44: E38-44.

4. Druyts E, Thorlund K, Wu P, Kanters, S, Yaya S, Cooper CL, Mills EJ. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 961-7.

5. Jonas MM, Schwarz KB, Gonzalez-Peralta R, Lobritto S, Molleston JP, Murray KF, Rosenthal P, et al. Long-term growth outcomes in children treated for chronic hepatitis C. J Pediatr 2014; 165: 1252-4.

6. Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, et al. Long-term follow-up of children treated with peginterferon and ribavirin for hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2017; 64: 89-94.

7. Tahata Y, Hiramatsu N, Oze T, Morishita N, Harada, N, Yamada R, Yakushijin T, et al. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. J Gastroenterol 2016; 51: 252-9.